At 59-month median follow-up , superior efficacy of EC-Doc [ versus FEC ( a combination of 5-fluorouracil , epirubicin , and cyclophosphamide ) ] was seen in EFS and OS : 5-year EFS : 89.8 % versus 87.3 % ( P = 0.038 ) ; 5-year OS : 94.5 % versus 92.8 % ( P = 0.034 ) ; both tests one-tailed .